SL 017

Drug Profile

SL 017

Alternative Names: ACP-SL017; ACP-SL017 - Altachem Pharma; Hypocrellin-based product (HB) - Altachem Pharma; SL017; Topical HB

Latest Information Update: 30 Jul 2013

Price : $50

At a glance

  • Originator Quest PharmaTech
  • Class Antineoplastics; Perylenes; Quinones; Small molecules
  • Mechanism of Action Photosensitisers; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acne; Actinic keratosis

Most Recent Events

  • 02 Jun 2008 Final efficacy and adverse events data from a phase I trial in Actinic keratosis released by Quest PharmaTech
  • 13 Jun 2007 Quest PharmaTech completes enrolment in its phase I trial for actinic keratosis in Canada
  • 16 May 2007 The Sonolight technology has been licensed to Paramount Biosciences worldwide, excluding Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top